Bone Biologics Corporation
BBLGHealthcare|Biotechnology|US
$0.33
+0.01 (+3.00%)
DCF Value
$4.22
Tangible Book / Share
$1.59
Cash / Share
$1.63
Financials
Financial Snapshot
Market Cap
$1.1M
Enterprise Value
-$5.0M
Revenue (TTM)
$0.00
Net Income (TTM)
-$2.8M
Cash & Investments
$6.1M
Net Cash
$6.1M
Free Cash Flow (TTM)
-$2.6M
Operating CF (TTM)
-$2.6M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$6.1M
Quarterly Burn
$642.4K
Monthly Burn
$214.1K
Est. Runway
~9.5 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $620.4K | $690.3K | $955.4K | $24.1K | $0.00 | $6.7M | $7.5M | $3.0M | $3.3M | $5.3M | $6.1M | |
| Operating Cash Flow | -$7.3M | -$3.3M | -$4.1M | -$3.3M | -$426.9K | -$1.2M | -$3.6M | -$9.6M | -$4.1M | -$2.7M | -$2.6M | |
| Free Cash Flow | -$7.3M | -$3.3M | -$4.1M | -$3.3M | -$426.9K | -$1.2M | -$3.6M | -$9.6M | -$4.1M | -$2.7M | -$2.6M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$5.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $6.8M | $3.4M | $4.4M | $2.3M | $402.8K | $7.9M | $4.4M | $5.0M | $4.4M | $4.7M | $2.6M |
R&D Spending
R&D (TTM)
$950.1K
R&D Intensity
—
R&D Growth vs Prior
-10.4%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $11.6M | -$1.2M | $104.5K | $1.1M | $340.7K | $82.0K | $1.6M | $6.9M | $2.1M | $1.1M | $950.1K | |
| SG&A | $6.2M | $3.8M | $2.7M | $1.4M | $484.3K | $1.0M | $2.1M | $2.5M | $2.1M | $2.2M | $2.1M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $700.00 | $96.00 | $96.00 | $50.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | -$700.00 | -$96.00 | -$96.00 | -$50.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $11.6M | -$1.2M | $104.5K | $1.1M | $340.7K | $82.0K | $1.6M | $6.9M | $2.1M | $1.1M | $950.1K | |
| SG&A | $6.2M | $3.8M | $2.7M | $1.4M | $484.3K | $1.0M | $2.1M | $2.5M | $2.1M | $2.2M | $2.1M | |
| Operating Income | -$20.4M | -$2.6M | -$2.8M | -$2.4M | -$825.0K | -$1.1M | -$3.7M | -$9.4M | -$4.2M | -$3.2M | -$3.0M | |
| Interest Expense | $2.6M | $4.4M | $1.2M | $975.8K | $998.1K | $805.1K | $731.7K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$21.0M | -$7.0M | -$4.4M | -$3.4M | -$1.8M | -$1.6M | -$1.5M | -$8.9M | -$4.1M | -$3.1M | -$2.8M | |
| Net Income | -$25.9M | -$7.1M | -$4.4M | -$3.4M | -$1.8M | -$1.6M | -$1.5M | -$8.9M | -$4.1M | -$3.1M | -$2.8M | |
| EPS (Diluted) | -24840.00 | -6480.00 | -3173.58 | -66.97 | -35.68 | -37.35 | -31.20 | -34.01 | -4.83 | -2.65 | -1.66 | |
| EBITDA | -$20.4M | -$2.6M | -$2.8M | -$2.4M | -$825.0K | -$805.6K | -$752.9K | $479.3K | $107.2K | -$3.1M | -$2.9M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 | 0.04 | 0.05 | 0.26 | 1.52 | 1.17 | 3.74 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $620.4K | $690.3K | $955.4K | $24.1K | $0.00 | $6.7M | $7.5M | $3.0M | $3.3M | $5.3M | $6.1M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $700.9K | $795.5K | $1.0M | $30.8K | $0.00 | $6.7M | $8.5M | $3.7M | $3.9M | $5.8M | $6.4M | |
| Total Assets | $973.1K | $795.7K | $1.0M | $30.8K | $0.00 | $6.7M | $8.5M | $3.7M | $3.9M | $5.8M | $6.4M | |
| Total Current Liabilities | $1.5M | $961.8K | $9.6M | $578.4K | $13.7M | $99.9K | $2.5M | $831.4K | $377.7K | $418.6K | $480.8K | |
| Long-Term Debt | $7.6M | $8.2M | $0.00 | $11.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $9.6M | $9.2M | $9.6M | $11.9M | $13.7M | $99.9K | $2.5M | $831.4K | $377.7K | $418.6K | $480.8K | |
| Stockholders' Equity | -$8.4M | -$8.4M | -$8.6M | -$11.9M | -$13.7M | $6.6M | $5.9M | $2.9M | $3.5M | $5.4M | $6.0M | |
| Retained Earnings | -$52.1M | -$59.2M | -$63.6M | -$67.0M | -$68.9M | -$70.5M | -$72.0M | -$80.9M | -$85.0M | -$88.1M | -$90.3M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.3M | -$3.3M | -$4.1M | -$3.3M | -$426.9K | -$1.2M | -$3.6M | -$9.6M | -$4.1M | -$2.7M | -$2.6M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$5.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$7.3M | -$3.3M | -$4.1M | -$3.3M | -$426.9K | -$1.2M | -$3.6M | -$9.6M | -$4.1M | -$2.7M | -$2.6M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $6.8M | $3.4M | $4.4M | $2.3M | $402.8K | $7.9M | $4.4M | $5.0M | $4.4M | $4.7M | $2.6M | |
| Issuance of Stock | $2.5M | $700.0K | $4.4M | $0.00 | $0.00 | $6.9M | $4.4M | $5.0M | $2.6M | $4.7M | $2.7M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $3.1M | $2.7M | $0.00 | $2.3M | $402.8K | $1.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $3.5M | -$584.0K | $516.6K | $49.7K | $60.0K | $207.0K | $266.6K | $152.6K | $188.8K | $256.4K | $80.9K | |
| Net Change in Cash | -$494.7K | $69.9K | $265.1K | -$931.2K | -$24.1K | $6.7M | $862.9K | -$4.5M | $298.6K | $2.0M | $39.0K |
Dilution Tracker
Shares outstanding grew 2197.4% over 5 years — significant dilution
Shares Outstanding
3M
5-Year Share Growth
+2197.4%
Stock Issuance (TTM)
$2.7M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 | 0.04 | 0.05 | 0.26 | 1.52 | 1.17 | 3.74 | |
| Change vs Prior % | — | 3.4% | 29.1% | 3563.2% | 0.0% | -15.7% | 10.5% | 452.1% | 476.5% | -22.6% | 218.1% | |
| Stock Issuance | $2.5M | $700.0K | $4.4M | $0.00 | $0.00 | $6.9M | $4.4M | $5.0M | $2.6M | $4.7M | $2.7M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $3.5M | -$584.0K | $516.6K | $49.7K | $60.0K | $207.0K | $266.6K | $152.6K | $188.8K | $256.4K | $80.9K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 309.4% | 84.0% | 51.5% | 28.9% | 13.3% | -24.5% | -25.0% | -307.9% | -118.0% | -57.8% | -57.1% | |
| ROA % | -2659.5% | -886.3% | -425.7% | -11109.8% | 0.0% | -24.1% | -17.5% | -239.4% | -106.5% | -53.6% | -44.2% | |
| ROIC % | -5111.7% | 1581.2% | -694.6% | 446.9% | 41.9% | -16.8% | -61.6% | -324.4% | -121.1% | -60.2% | -50.6% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 84.3% | 86.3% | 0.0% | 47.9% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | -70.2% | 87.1% | -6.2% | 12.3% | 66.3% | -33.7% | -232.3% | -157.2% | 55.3% | 23.3% | |
| Net Income | -86.5% | 72.8% | 37.2% | 22.7% | 46.7% | 11.7% | 7.8% | -502.8% | 54.1% | 24.4% | |
| EPS (Diluted) | -40.8% | 73.9% | 51.0% | 97.9% | 46.7% | -4.7% | 16.5% | -9.0% | 85.8% | 45.1% | |
| Operating Cash Flow | -106.7% | 54.6% | -23.3% | 20.8% | 86.9% | -187.8% | -190.3% | -167.9% | 56.8% | 34.8% | |
| Free Cash Flow | -106.6% | 54.6% | -23.3% | 20.8% | 86.9% | -187.8% | -190.3% | -167.9% | 56.8% | 34.8% | |
| R&D Expense | 216.5% | -110.3% | 108.8% | 948.1% | -68.9% | -75.9% | 1824.9% | 337.4% | -69.2% | -50.2% | |
| SG&A Expense | -25.0% | -38.8% | -29.7% | -49.7% | -64.2% | 110.8% | 104.3% | 20.8% | -17.1% | 4.1% | |
| Total Assets | -53.2% | -18.2% | 30.8% | -97.0% | -100.0% | 0.0% | 27.3% | -56.0% | 3.3% | 50.1% | |
| Book Value / Share | -15.0% | 6.0% | 20.7% | 96.2% | -15.4% | 157.0% | -18.3% | -91.2% | -79.2% | 99.3% | |
| Debt | 72.4% | -6.1% | 9.4% | 25.8% | 3.6% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 32.1% | 3.4% | 29.1% | 3563.2% | 0.0% | -15.7% | 10.5% | 452.1% | 476.5% | -22.6% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.21
10Y Low / Med / High0.32 / 2.46 / 16.59
EV/EBITDA1.72
10Y Low / Med / High0.46 / 8.57 / 48.81
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$4.22
Tangible Book / Share
$1.59
Net Current Assets / Share
$1.76
Graham Net-Net
$1.50
Cash / Share
$1.63
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.13 | -0.51 | -1.04 | -49.50 | -92.92 | -67.92 | -4.85 | -0.80 | -1.17 | -0.55 | -0.20 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -0.41 | -0.43 | -0.54 | -14.25 | -12.35 | 16.59 | 1.21 | 2.46 | 2.46 | 0.32 | 0.21 | |
| EV/EBITDA | -0.57 | -4.24 | -4.54 | -73.70 | -219.15 | -127.13 | 0.46 | 8.57 | 48.81 | 1.17 | 1.72 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-18.61
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Net Income | -$1.4M | -$693.2K |
| EPS | $-1.18 | $-0.59 |
| # Analysts (EPS) | 1 | 1 |